<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02233205</url>
  </required_header>
  <id_info>
    <org_study_id>2014YJZ11</org_study_id>
    <nct_id>NCT02233205</nct_id>
  </id_info>
  <brief_title>Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System</brief_title>
  <official_title>Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the
      therapeutic effects. The main purpose is to identify the safety of combining ultrasonic
      microbubbles and chemotherapeutics to treat malignant neoplasms of hepatic metastases from
      alimentary system and pancreatic carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the
      therapeutic effects.

        1. Main purpose

             1. To identify the safety of combining ultrasonic microbubbles and chemotherapeutics
                to treat malignant neoplasms of hepatic metastases from alimentary system and
                pancreatic carcinoma.

             2. To explore the largest mechanical index and ultrasonic treatment time which
                patients can endure.

        2. Secondary purpose

             1. To observe tumor clinical benefit rate (CR+PR+SD).

             2. To evaluate the preliminary effect,such as time to failure(TTF), time to death(TTD)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>microbubbles &amp; platinum and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasonic microbubbles</intervention_name>
    <description>inject 1ml once and five times in 20min, locate the probe on the lesion at the same time</description>
    <arm_group_label>microbubbles &amp; platinum and gemcitabine</arm_group_label>
    <other_name>Sonovue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>platinum and gemcitabine</intervention_name>
    <description>Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.</description>
    <arm_group_label>microbubbles &amp; platinum and gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of liver metastases from alimentary system and pancreatic
             carcinoma

          -  Failed routine chemotherapy

          -  Neoplasms can be evaluated by imaging

          -  ECOGã€Š2

        Exclusion Criteria:

          -  Have systematic chemotherapy in 2 weeks

          -  Be allergic to ultrasonic microbubbles and chemotherapeutics

          -  Uncontrolled high blood pressure, cardiovascular disease

          -  Active bleeding

          -  Have serious mental and psychological disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Yan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Shen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Wei, Doctor</last_name>
    <phone>0086-10-88196195</phone>
    <email>13681408183@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanjie Wang, Doctor</last_name>
    <phone>0086-10-88196941</phone>
    <email>philinsss@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Yang, Doctor</last_name>
      <phone>0086-10-88196195</phone>
      <email>13681408183@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanjie Wang, Doctor</last_name>
      <phone>0086-10-88196941</phone>
      <email>philinsss@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Li, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Yang, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jifang Gong, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kotopoulis S, Dimcevski G, Gilja OH, Hoem D, Postema M. Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. Med Phys. 2013 Jul;40(7):072902. doi: 10.1118/1.4808149.</citation>
    <PMID>23822453</PMID>
  </results_reference>
  <results_reference>
    <citation>Dewitte H, Van Lint S, Heirman C, Thielemans K, De Smedt SC, Breckpot K, Lentacker I. The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy. J Control Release. 2014 Nov 28;194:28-36. doi: 10.1016/j.jconrel.2014.08.011. Epub 2014 Aug 22.</citation>
    <PMID>25151979</PMID>
  </results_reference>
  <results_reference>
    <citation>Fan Z, Kumon RE, Deng CX. Mechanisms of microbubble-facilitated sonoporation for drug and gene delivery. Ther Deliv. 2014 Apr;5(4):467-86. doi: 10.4155/tde.14.10. Review.</citation>
    <PMID>24856171</PMID>
  </results_reference>
  <results_reference>
    <citation>Feichtinger GA, Hofmann AT, Slezak P, Schuetzenberger S, Kaipel M, Schwartz E, Neef A, Nomikou N, Nau T, van Griensven M, McHale AP, Redl H. Sonoporation increases therapeutic efficacy of inducible and constitutive BMP2/7 in vivo gene delivery. Hum Gene Ther Methods. 2014 Feb;25(1):57-71. doi: 10.1089/hgtb.2013.113. Epub 2013 Nov 27.</citation>
    <PMID>24164605</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2014</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Kun Yan</investigator_full_name>
    <investigator_title>chief director</investigator_title>
  </responsible_party>
  <keyword>microbubble</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>alimentary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

